- cafead   Dec 17, 2020 at 06:52: PM
via AbbVie's aiming to make the most out of its new moneymaker Botox, gained in its Allergan megamerger last year, and it just scored a legal win—against a much smaller rival—that should help.
On Wednesday, the United States International Trade Commission issued a 21-month ban on the import or sale of Evolus’ Jeuveau, a Botox competitor that launched in May 2019. Allergan and its partner Medytox had alleged Evolus and manufacturing partner Daewoong used stolen trade secrets to manufacture Jeuveau, while Evolus denied the claim.
article source
On Wednesday, the United States International Trade Commission issued a 21-month ban on the import or sale of Evolus’ Jeuveau, a Botox competitor that launched in May 2019. Allergan and its partner Medytox had alleged Evolus and manufacturing partner Daewoong used stolen trade secrets to manufacture Jeuveau, while Evolus denied the claim.
article source